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Cdk9, the kinase of the positive transcription elonga-
tion factor b, is required for processive transcription
elongation by RNA polymerase II. Cdk9 inhibition
contributes to the anticancer activity of many Cdk
inhibitors under clinical investigation and hence
there is interest in selective Cdk9 inhibitors. DRB
(5,6-dichlorobenzimidazone-1-b-D-ribofuranoside) is
a commonly used reagent for Cdk9 inhibition in cell
biology studies. The crystal structures of Cdk9 and
Cdk2 in complex with DRB reported here describe
the molecular basis for the DRB selectivity toward
Cdk9. The DRB chlorine atoms form halogen bonds
that are specific for the Cdk9 kinase hinge region.
Kinetic and thermodynamic experiments validate
the structural findings and implicate the C-terminal
residues of Cdk9 in contributing to the affinity for
DRB. These results open the possibility to exploit
halogen atoms in inhibitor design to specifically
target Cdk9.
INTRODUCTION
The positive transcription elongation factor b (P-TEFb; Cdk9/Cy-
clin T [CycT]) stimulates transcription elongation by RNA
polymerase II (Pol II). After initiation of transcription by Pol II,
transcription is halted by the repressors 5,6-dichlorobenzimida-
zone-1-b-D-ribofuranoside (DRB)-sensitivity-inducing factor
(DSIF) and the negative elongation factor (NELF). In the presence
of these repressors Pol II produces short mRNA transcripts and
pauses. Cdk9 as a subunit of P-TEFb is recruited to the halted
transcription complex and phosphorylates DSIF, NELF and the
Pol II C-terminal domain (CTD) (Core and Lis, 2008; Peterlin
and Price, 2006; Yamada et al., 2006). These phosphorylations
relieve repressor activity and are accompanied by recruitment
of mRNA processing enzymes and the loss of NELF that together
allow transcription to progress to the elongation phase.
DRB has been established as an inhibitor of mRNA synthesis
(Sehgal et al., 1976) and is a widely used agent that specifically
inhibits transcription elongation, but not initiation. DRB inhibits
P-TEFb with a IC50 of 0.9–0.34 mM (Peng et al., 1998; Wang
and Fischer, 2008). DRB is selective for Cdk9 and the IC50 value
is two orders of magnitude less than the action of DRB toward
other Cdks (Cdk1/CycB:IC5017 mM [Wang and Fischer, 2008]).Chemistry & Biology 17, 931–9P-TEFb is a validated drug target in oncology, virology, and
cardiology (Wang and Fischer, 2008). It is most relevant as a
target when the diseased state has arisen from the upregulation
of proteins that have unstable mRNA (Lam et al., 2001).
Flavopiridol, a potent P-TEFb inhibitor (Ki 3 nM) has advanced
to Phase II clinical trials for the treatment of chronic lymphocytic
leukemia (Byrd et al., 2007). Although DRB is not a drug candi-
date, understanding its mode of P-TEFb inhibition is relevant
for the study of transcription regulation andmay allow the design
of more specific inhibitors to exploit the clinical potential of
P-TEFb inhibition.
Protein kinase structural studies have shown that adenosine
triphosphate (ATP) binds with the adenine moiety docked into
a hydrophobic cleft between the two lobes of the kinase domain,
interacting with the kinase hinge region through hydrogen bonds
(Figure 1). Many kinase inhibitors bind at this highly conserved
nucleotide binding site. For example, flavopiridol makes ATP-like
hydrogen bond interactions (Baumli et al., 2008). DRB is an
adenosine analog and hence it might be expected to bind to
the ATP binding site (Figure 1). However, in DRB the hydrogen
bonding groups are replaced by chlorine. It is not clear how
DRB might bind to P-TEFb and nor is it understood how DRB
achieves specificity for Cdk9 compared with other Cdks.
To answer these questions, we have determined the crystal
structures of Cdk9/CycT and Cdk2/CycA in complex with
DRB. Bound to Cdk9, DRB interacts via its chlorine atoms
forming halogen bonds to the main chain carbonyl oxygens
from the hinge region whereas the adenine-like moiety and
ribose are accommodated in similar regions to those occupied
by ATP. DRB binds to Cdk2 in an alternative conformation that
exploits only one halogen bond and a halogen/p electron inter-
action. It is proposed that the inherent flexibility of Cdk9 in
complex with CycT compared to the more rigid conformation
of Cdk2 in complex with CycA contributes to specificity and
affinity.RESULTS
The DRB Binding Site in Cdk9/CycT and Cdk2/CycA
The structures of active phospho-Cdk9330 (residues 1–330)/
CycT (residues 1–259) and phospho-Cdk2/CycA (residues
175–432) in complex with DRB were solved at 2.8 A˚ and 2.1 A˚
resolution, respectively (Table 1). In both Cdk/Cyclin complexes
DRB binds to the ATP binding site adopting different, kinase-
specific, orientations.
In Cdk9/CycT, the planar benzimidazole moiety locates to
the adenine binding site and is sandwiched between Ile25 in36, September 24, 2010 ª2010 Elsevier Ltd All rights reserved 931
Figure 1. The Chemical Structures of Adenosine Triphosphate,
Flavopiridol, and 5,6-Dichlorobenzimidazone-1-b-D-Ribofuranoside
Drawn Bound to a Schematic Representation of the Cdk9 Hinge
Region
Table 1. Data Collection and Refinement Statistics
Cdk9/CycT/DRB Cdk2/CycA/DRB
Data collection
Beam line ESRF ID23-1 ESRF ID14-4
Space group
and unit cell (A˚)
H3 P212121
a = b = 173.8,
c = 99.2
a = 74.3, b = 132.3,
c = 148.4
Resolution (A˚)
(highest resolution shell)
38.5–2.8
(2.95–2.80)
59.5–2.1
(2.21–2.10)
Total observations 153,549 (22,767) 352,234 (51,715)
Unique 27,472 (3998) 87,151 (12,597)
Rmerge 0.066 (0.597) 0.098 (0.595)
Multiplicity 5.6 (5.7) 4.0 (4.1)
Mean I/sI 18.6 (2.2) 10.2 (2.6)
Completeness % 99.9 (100) 99.9 (100)
Refinement
Total number of atoms 4701 9419
Number of waters 28 525
R (highest resolution shell) 17.5
(29.3 [2.85–2.8])
18.0
(26.6 [2.12–2.1])
Rfree (highest resolution shell) 21.4
(32.6 [2.85–2.8])
21.9
(29.9 [2.12–2.1])
Rmsd bonds (A˚) 0.008 0.007
Rmsd angles () 1.2 1.1
Rmsd: root-mean-square-deviation.
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P-TEFb Inhibition by DRBthe N-terminal lobe and Leu156 in the C-terminal lobe of Cdk9
(Figure 2A). The two chlorine atoms of the DRB benzimidazole
moiety contact the hinge region: there are contacts from DRB
Cl1 to the main chain oxygen of Asp104 (distance: 2.7 A˚; angles:
C = O—Cl1 129; C-Cl1—O 174) and from DRB Cl2 to the main
chain oxygen of Cys106 (3.0 A˚; angles: C =O—Cl2 127; C-Cl2—
O 160) (Figure 2C). These contacts are consistent with geome-
tries reported for halogen bonds, defined as interactions where
the approach of the halogen to an electronegative atom is closer
than the sum of their van der Waals (vdW) radii (Auffinger et al.,
2004). For a chlorine (vdW radius 1.75 A˚) and oxygen (vdW radius
1.52 A˚) the distance is 3.27 A˚. In addition there is a contact from
Cl2 to NH Cys106 (3.5 A˚; angle Cl2—N-H = 148) consistent
with a contact in which the halogen acts as a hydrogen bond
acceptor (Lu et al., 2009b). The only other polar contact
observed between DRB and Cdk9 is a water-mediated interac-932 Chemistry & Biology 17, 931–936, September 24, 2010 ª2010 Eltion between the benzimidazole N2 and the backbone NH group
of Asp167. The halogen bonds appear to be the major
determining factor for the specific orientation of DRB bound to
Cdk9.
In Cdk2/CycA, DRB also binds to the ATP site but in a different
orientation (Figures 2B and 2D). Cl1 contacts the backbone
carbonyl of the hinge-region Glu81 (distance: 2.7A˚; angles:
C = O—Cl1 153; C-Cl1—O 166) making one contact that is
similar to a contact observed in Cdk9. Cl2 points toward the
gatekeeper residue Phe80 at the back of the Cdk2 ATP binding
site such that the halogen contacts the p-electrons of the
phenylalanine ring (angle 70; distance to plane of ring: 4.0 A˚).
The ribofuranoside adopts a similar orientation in the Cdk2
bound structure as in Cdk9 but it is less ordered. This orientation
is achieved by a rotation of 121 around the C1-N1 bond that
connects the ribofuranoside to the benzimidazole moiety. There
is a direct hydrogen bond from the ribofuranoside to the main
chain nitrogen of Gly13. There are also several water-bridged
interactions of DRB with Cdk2. These include water bridges
between N2 in the benzimidazole moiety and the backbone
carbonyls of Leu83 and His84, and the ribofuranoside to
Asp86 and to Asn132 (Figure 2B). The higher resolution of the
Cdk2 structure (2.1 A˚) compared with that for Cdk9 (2.8 A˚)
permitted a greater number of water molecules to be built with
confidence into the structure.
Refinement of the occupancy of DRB in the Cdk2 bound
structure suggested that 12% of the DRB molecules bind in
a Cdk9-like orientation. Thus it is possible for DRB to adopt
a Cdk9 binding mode also in Cdk2, but this is not the preferred
orientation. Residues 107–109 in the hinge region of Cdk9 adoptsevier Ltd All rights reserved
Figure 2. DRB Binding to Cdk9 and Cdk2
(A) Details of the Cdk9/CycT ATP binding site
complexed with DRB.
(B) Details of the Cdk2/CycA ATP binding site
complexed with DRB. Inhibitor carbon atoms are
colored yellow and contacting residues are drawn
as stick models. Halogen and hydrogen bonds are
indicated by dotted lines. Waters are shown as
crosses.
(C and D) Detailed views of the halogen bonds of
DRB bound to Cdk9 and Cdk2, respectively.
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P-TEFb Inhibition by DRBa different path to that of the corresponding residues in Cdk2 so
that the carbonyl of Cys106 is displaced backward by 0.8 A˚ with
respect to the corresponding residue in Cdk2 (Leu83). This small
change in position allows more space to optimally accommo-
date DRB Cl2 and form the halogen bonds to the Cdk9 hinge
region. Thus it seems that the halogen bond formation requires
a very specific environment and is therefore a determinant of
selectivity.
DRB Binding Induces Conformational Changes
in Cdk9 but Not Cdk2
Cdk9 is less constrained by contacts to CycT than Cdk2 bound
to CycA and is therefore inherently more flexible (Baumli et al.,
2008). On DRB binding to Cdk9/CycT, the two kinase lobes
rotate around the Phe105-Cys106 peptide bond in the hinge
region by 8 and move toward each other to accommodate
the inhibitor in the ATP binding site (Figure 3A). The major struc-
tural changes in Cdk9 are in the glycine-rich loop, which moves
downward to enclose the inhibitor. Concomitantly, the b3-aC
loop folds over the glycine-rich loop and locks it in its downward
position (gray to blue in Figure 3A). Leu51 fills the hydrophobic
pocket previously occupied by Phe30 of the glycine-rich loop.
These changes are specific to Cdk9 and do not occur in the
Cdk2/CycA bound structure (gray to orange in Figure 3B). All
other Cdks have a charged residue at the position equivalent
to Leu51 in Cdk9 (e.g., Arg36 in Cdk2). These residues are
unable to fill the vacant hydrophobic pocket created by the shift
of the glycine-rich loop.
Although DRB makes more polar contacts with Cdk2 than it
does when bound to Cdk9, DRB bound to Cdk9/CycT is able
to exploit the greater flexibility of the kinase to increase favorableChemistry & Biology 17, 931–936, September 24, 2010van der Waals contacts. The downward
conformations of the glycine-rich loop
and the b3-aC loop are reminiscent of
those observed on flavopiridol binding
to Cdk9 and may account for the
increased potency toward Cdk9 for both
inhibitors.
The Cdk9 C Terminus Contributes
to the Inhibitor Affinity
To validate our structural results, we
measured the ability of DRB to inhibit
the crystallized variants of the Cdk/
Cyclin complexes. The measured IC50
values are 3.6 mM for the C-terminallytruncated Cdk9 (residues 1–330)/CycT, 0.23 mM for the full-
length Cdk9 (residues 1–372)/CycT, and 65 mM for Cdk2/
CycA (Table 2; see Figure S1A available online). The apparent
increase in effectiveness of DRB as an inhibitor of Cdk9/CycT
compared with Cdk2/CycA is consistent with the structural
results. The IC50 value (0.23 mM) for Cdk9FL/CycT is consistent
with published results (IC50 values between 0.9 and 0.34 mM
[Peng et al., 1998; Wang and Fischer, 2008]) and because
this value is lower than that for the truncated Cdk9330, it
suggests that the C-terminal portion of the full-length Cdk9
influences the inhibition by DRB. Examination of the structure
of Cdk9/CycT suggests that the C-terminal residues could
wrap around the catalytic site further shielding the inhibitor
from solvent (Figure 3A) and stabilize the adopted kinase
conformation. Indeed, when we test the stability of the Cdk9/
CycT/DRB variants in thermal denaturation assays Cdk9FL/
CycT shows a small increase (49.26 ± 0.05C) in its melting
point compared with Cdk9330/CycT (48.76 ± 0.07
C). This
stabilization is specific to DRB and does not occur in the other
Cdk9/inhibitor complexes tested (Figure S1B) suggesting that
the C-terminal residues contribute to the overall stability of
the DRB complexes.
DISCUSSION
The binding of DRB to Cdk9/CycT is mostly directed by halogen
bonds. These interactions are analogous to hydrogen bonds
with the halogen acting as the electron acceptor and the oxygen
acting as the electron donor. Many examples of halogen bonds
have been identified in the Cambridge Crystallographic
Database for small molecule compounds (Lommerse et al.,ª2010 Elsevier Ltd All rights reserved 933
Figure 3. DRB Binding Is Accompanied by
Conformational Change
(A) Cdk9/CycT/DRB (green) and Cdk9/CycT/ATP
(gray; 3BLQ) are superimposed on their C-terminal
lobes. Conformational changes occur in the
glycine-rich loop, the b3-aC loop (blue) and in
a rotation of the Cdk9 N-terminal kinase domain
around Cys106 in the hinge region. The C-terminal
residue Met327 is marked and the arrow indicates
the possible direction of C-terminal residues
331–372.
(B) Cdk2/CycA/DRB (orange) and Cdk2/CycA/
ATP (gray; 1QMZ) have been superposed as in
(A). The Cyclin subunits are omitted. There are
breaks in the electron density in Cdk9 between
residues 88–96 (b4-b5 loop) and in Cdk2 between
residues 37–41 (b3-aC loop).
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P-TEFb Inhibition by DRB1996). 248 O—X interactions have been described in the PDB
demonstrating that they also have roles in macromolecular
assemblies (Lu et al., 2009a). A systematic analysis by Auffinger
et al. (2004) identified over 100 short halogen contacts in the
PDB, of which 70% were C = O—X, where X is Cl, Br, or I.
These had a preferred geometry with angles C = O—X 120
and C-X—O 165 or 145.
Ab initio electrostatic potential calculations show that the
halogen develops an electropositive crown along the C-X axis,
which is surrounded by a neutral region and then by an electro-
negative belt (Auffinger et al., 2004). The magnitude of the effect
increases such that I > Br > Cl and is modulated by the chemical
context of the halogen atom. There are larger effects for
halogens associated with electron withdrawing groups so that,
for example, the effects are more pronounced for halogens in
aromatic than aliphatic compounds (Auffinger et al., 2004). This
charge distribution allows both, electrophile ‘‘head-on’’ and
nucleophile ‘‘side-on’’ interactions with halogens. In the Cdk9/
DRB complex both types of interactions are exploited: the
carbonyl oxygens are directed toward the positive crown of
the chlorines in head on interactions and these contacts are
augmented by a side on interaction in which the N-H is directed
toward the halogen electronegative belt.
A specific chemical environment is required for halogen bonds
to be formed. This is demonstrated by the current results where
DRB binds in alternative ways to Cdk9/CycT and to Cdk2/CycA.
The only other structural result with DRB bound to a kinase isTable 2. Cdk9 and Cdk2 Inhibition by DRB and Melting
Temperature of CDK9
Kinase IC50 (mM) Tm (
C)
Cdk9FL/CycT 0.24 49.26 ± 0.05
CDK9330/CycT 3.58 48.76 ± 0.07
Cdk2/CycA 65 ND
DRB: 5,6-dichlorobenzimidazone-1-b-D-ribofuranoside; ND: not deter-
mined. Errors are given asmaximal deviations. Primary data are available
in Figure S1.
934 Chemistry & Biology 17, 931–936, September 24, 2010 ª2010 Elwith CK2 where DRB makes lower affinity interactions at the
ATP binding site and at a second allosteric site (Ki competitive:
29 mM, Ki noncompetitive: 39.7 mM [Raaf et al., 2008]). The inhib-
itor binding mode at the ATP site is different from both the Cdk9
and Cdk2 interactions and DRB forms a weak halogen bond to
the CK2 hinge region. Halogen bond formation contributes to
the specific molecular recognition in DRB/Cdk9 interactions.
However, halogen bonds are weak interactions. The binding
energy of a halogen bond has been estimated to range from
about half to slightly more than that of a hydrogen bond, depend-
ing on the geometry of the binding site. The formation of the
halogen bonds cannot account for the potency of DRB toward
Cdk9. Rather, vdW contacts and stabilization of a favorable
kinase conformation also contribute to the higher affinity of the
inhibitor toward Cdk9 compared with Cdk2. This effect is further
increased by the C-terminal kinase residues that stabilize the
adopted conformation.
A diversity of binding modes has been observed with the CK2
inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) and its deriva-
tives. TBB binds to CK2 without forming halogen bonds to the
kinase hinge region (Battistutta et al., 2005). Modifications of
TBB that remove the negative charge of its triazole ring did
generate compounds that bind to CK2 utilizing halogen bonds
to the main chain carbonyl oxygens in the hinge region. All
TBB derivatives are of similar potency toward CK2 ranging
from IC50 of 0.14 mM to 0.74 mM, and slightly higher affinity
does not correlate with the formation of halogen bonds (Battis-
tutta et al., 2005). TBB also binds to the Cdk2/CycA ATP
binding site but with a much lower affinity (IC50 = 16 mM
[De Moliner et al., 2003]). In complex with Cdk2 TBB exploits
the halogen-p interaction observed in the Cdk2-DRB structure
and forms halogen bonds to the main chain carbonyl oxygens
in the hinge region, adopting the binding mode of the TBB
derivatives bound to CK2. Similar to the Cdk9 DRB interaction
the potency of TBB and derivatives toward CK2 has been
attributed to the induced conformational changes and burying
of the inhibitor.
Taken together it is apparent that halogen bonds can confer
selectivity toward a given kinase because they determine thesevier Ltd All rights reserved
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P-TEFb Inhibition by DRBorientation in which the inhibitor is bound. However, additional
contributions are needed to increase the potency of the com-
pounds. Our structural studies can serve as the basis
to improve the inhibitory potency of DRB without losing its
specificity for Cdk9.
SIGNIFICANCE
5,6-dichlorobenzimidazone-1-b-D-ribofuranoside (DRB) is
a widely used inhibitor of transcription elongation, which
acts by specifically inhibiting P-TEFb, the positive transcrip-
tion elongation factor b (Cdk9/CycT). We describe the
binding mode of DRB to a C-terminally truncated Cdk9/
CycT. DRB binds to the ATP binding site via halogen bonds
from the chlorine to the main chain carbonyl oxygen atoms
in the hinge region that connects the N- and C-terminal
kinase lobes. Halogen bond formation determines the
orientation of DRB within the ATP binding site. In addition,
inhibitor binding induces conformational changes in the
glycine-rich loop and the b3-aC loop that enclose the
inhibitor. These interactions contribute to a high affinity
interaction that is further enhanced by the Cdk9 C-terminal
residues 331–372. In contrast, DRB binding to Cdk2/CycA
is 282-fold weaker. The more restricted ATP site results in
DRB binding in a different orientation to Cdk2/CycA. The
structural studies indicate that halogen bonds contribute
to binding and specificity and may be exploited to develop
inhibitors that specifically target Cdk9.
EXPERIMENTAL PROCEDURES
Cdk9 (residues 1–330)/CycT1 (residues 1–259) was crystallized as described
(Baumli et al., 2008). Crystals were soaked in the mother liquor containing
15% glycerol and 250 mM DRB for 30 min before cryo-cooling in liquid
nitrogen. Cdk2 (residues 1–298)/CycA (residues 174–432) was prepared as
described (Brown et al., 1999) and incubated with 2.6 mM DRB for 30 min.
Insoluble DRB was removed by filtration (Amicon) before crystallization.
Co-crystals were grown in 1.1 M (NH4)2SO4, 100 mM HEPES pH 7.0,
5 mM dithiothreitol (DTT), cryo-protected in 7 M sodium formate containing
DRB.
Data were processed using MOSFLM and programs from CCP4 (1994).
Structures were solved with PHASER (McCoy et al., 2007) and improved by
alternative rebuilding in COOT (Emsley and Cowtan, 2004) and refinement
with PHENIX.REFINE (Afonine et al., 2005).
Kinase assays were carried out using a GST fusion of the Pol II CTD
as a substrate for both kinases. Ten microliter reactions containing 15 mg
GST-CTD, 12.5 ng of the respective Cdk/Cyclin complex in 10 mM ATP,
10 mM MgCl2, 50 mM Tris/HCl pH 8.0, 0.2 mCi g-
32P-labeled ATP were
incubated for 5 min at 30C and the reaction terminated by the addition of
sodium dodecyl sulfate sample buffer. Samples were analyzed by sodium
dodecyl sulfate polyacrylamide gel electrophoresis and autoradiography.
Data were fitted with GraphPad Prism version 5.02 (www.graphpad.com).
Melting curves were determined using 1 mM of the respective Cdk/Cyclin
complex with 1:1000 dilution of Sypro Orange (Molecular Probes) and 33 mM
of the corresponding inhibitor in 20 mM HEPES pH 7.5, 500 mM NaCl, 10%
glycerol, and 5 mM DTT. Spectra were obtained on a Stratagene mx3005P
QPCR machine by following Sypro orange incorporation and the concurrent
increase in fluorescence intensities at 570 nm.
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